(Q51021959)

27 March 2018

title

Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis (English)

1 reference

27 March 2018

main subject

phase II clinical trial

0 references

0 references

Robin R Deterding

1 reference

27 March 2018

Lisa M Lavange

1 reference

27 March 2018

Jean M Engels

1 reference

27 March 2018

Dave W Mathews

1 reference

27 March 2018

Sarah J Coquillette

1 reference

27 March 2018

Alan S Brody

1 reference

27 March 2018

Steve P Millard

1 reference

27 March 2018

Bonnie W Ramsey

1 reference

27 March 2018

Cystic Fibrosis Therapeutics Development Network and the Inspire 08-103 Working Group

1 reference

27 March 2018

language of work or name

English

0 references

publication date

19 April 2007

1 reference

27 March 2018

American Journal of Respiratory and Critical Care Medicine

published in

1 reference

27 March 2018

volume

176

1 reference

27 March 2018

issue

1 reference

27 March 2018

page(s)

362-369

1 reference

27 March 2018

Human airway ion transport. Part one.

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1238OC

Management of pulmonary disease in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1238OC

Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1238OC

Inhibition of amiloride-sensitive epithelial Na(+) absorption by extracellular nucleotides in human normal and cystic fibrosis airways

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1238OC

The CF salt controversy: in vivo observations and therapeutic approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1238OC

Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1238OC

Effect of aerosolized uridine 5'-triphosphate on mucociliary clearance in mild chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1238OC

Inhaled P2Y2 receptor agonists as a treatment for patients with Cystic Fibrosis lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1238OC

Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1238OC

Docosahexaenoic acid trials in cystic fibrosis: a review of the rationale behind the clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1238OC

Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1238OC

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1238OC

A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1238OC

Dornase alfa in early cystic fibrosis lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1238OC

Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1238OC

Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1238OC

A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1238OC

10.1164/RCCM.200608-1238OC

21 January 2018

Identifiers

DOI

1 reference

27 March 2018

1 reference

27 March 2018